|Bid||5.00 x 3000|
|Ask||0.00 x 1400|
|Day's range||5.12 - 5.34|
|52-week range||1.94 - 10.89|
|Beta (5Y monthly)||1.18|
|PE ratio (TTM)||18.01|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Recursion (RXRX) inks a collaboration with Roche to identify novel targets and advance medicines in areas of neuroscience and oncology indication. Shares rise.
The EMA accepts Sanofi's (SNY) regulatory submission seeking approval for olipudase alfa, a potential treatment for acid sphingomyelinase deficiency.
Merck (MRK) pauses enrolment for two phase III studies evaluating islatravir for pre-exposure prophylaxis of HIV-1 infection, following the recommendation of an external data monitoring committee.